Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of “Moderate Buy” by Brokerages
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price objective […]
More Stories
A Long Dockworker Strike May Bring More Pain to Consumers at the Grocery Store
By Mark Gilman Food prices went up 25 percent from 2019 to 2023 and were expected to increase by another...
High New Car Prices Spur Increased Incentives, but End of Low Cost Sedan Is Affecting Buyer Enthusiasm
By Mark Gilman If you’re in the market for an inexpensive second car, a first car for a family member,...
MFS Government Markets Income Trust (NYSE:MGF) Increases Dividend to $0.02 Per Share
MFS Government Markets Income Trust (NYSE:MGF – Get Free Report) declared a monthly dividend on Tuesday, October 1st, Wall Street...
Eaton Vance California Municipal Bond Fund (NYSE:EVM) Declares Monthly Dividend of $0.04
Eaton Vance California Municipal Bond Fund (NYSE:EVM – Get Free Report) announced a monthly dividend on Tuesday, October 1st, Wall...
Nuveen New York Select Tax-Free Income Portfolio (NXN) To Go Ex-Dividend on October 15th
Nuveen New York Select Tax-Free Income Portfolio (NYSE:NXN – Get Free Report) declared a monthly dividend on Tuesday, October 1st,...
Nuveen Select Tax-Free Income Portfolio Announces Monthly Dividend of $0.05 (NYSE:NXP)
Nuveen Select Tax-Free Income Portfolio (NYSE:NXP – Get Free Report) announced a monthly dividend on Tuesday, October 1st, Wall Street...